Sanofi (CHIX:SANP) Total Stockholders Equity: €69,207 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:SANP Sanofi SA CHIX:SANP
77 GF Score
Price €76.27
GF Value €107.51
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Sanofi Total Stockholders Equity?

Sanofi CHIX:SANP 77 Total Stockholders Equity is €69,207 Mil as of Jun. 2026. GuruFocus rates CHIX:SANP with a GF Score™ of 77/100 and a GF Value™ of €107.51 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Sanofi's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €69,207 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Sanofi's Book Value per Share for the quarter that ended in Jun. 2026 was €57.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Sanofi's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.34.

Sanofi  (CHIX:SANp) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Sanofi's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(69207-0)/1214.099
=57.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Sanofi's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(7253 + 16323) / 69207
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Total Stockholders Equity Related Terms

Sanofi Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Sanofi's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Total Stockholders Equity Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68,681.00 74,784.00 74,040.00 77,507.00 71,376.00

Sanofi Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72,690.00 77,507.00 70,008.00 71,376.00 69,207.00
CHIX:SANP
77GF Score
Sanofi SA CHIX:SANP
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €69,207 Mil mean?
Sanofi (CHIX:SANP) has a Total Stockholders Equity of €69,207 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Sanofi and its competitors.
Is Sanofi's Total Stockholders Equity too high?
Sanofi's current Total Stockholders Equity is €69,207 Mil. Overall, Sanofi has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Total Stockholders Equity compare to LLY and JNJ?
Sanofi's Total Stockholders Equity of €69,207 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Drug Manufacturers company?
A good Total Stockholders Equity depends on the Drug Manufacturers industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Sanofi and its competitors. Sanofi's current Total Stockholders Equity is €69,207 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Based on GuruFocus' analysis, Sanofi (CHIX:SANP) is currently considered Modestly Undervalued. The stock's GF Value™ is €107.51, compared to a current price of €76.27 — trading 29.1% below its estimated fair value. The current Total Stockholders Equity is €69,207 Mil. Sanofi's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Sanofi (CHIX:SANP), the current Total Stockholders Equity is €69,207 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (CHIX:SANP) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of €76.27 is trading 29.1% below its estimated GF Value™ of €107.51. GuruFocus considers Sanofi to be Modestly Undervalued.

Key valuation signals for CHIX:SANP:

  • Total Stockholders Equity: €69,207 Mil
  • GF Value™: €107.51 vs. price of €76.27 (29.1% below fair value)
  • GF Score™: 77/100 with 2 warning signs

No single metric tells the full story. See the CHIX:SANP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
77GF Score

Get the complete analysis for CHIX:SANP

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€76.27
Price
€107.51
GF Value